Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
European Patent Office intends to grant PHI patent on synthetic antibodies
PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
PHI visit WFIRM – Inside the World of Regenerative Medicine
PHI headed to the Wake Forest Institute for Regenerative Medicine (WFIRM) in Winston-Salem to visit, collaborate and attend the World Stem Cell Summit 2023.
HoloMonitor M4FL in the spotlight at EACR and ISSCR 2023
Recapping the scientific conferences EACR and ISSCR 2023 that put HoloMonitor M4FL in the spotlight at its world premiere.
BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
BIOSpektrum application article highlights HoloMonitor technology (in German)
PHI’s CSO, Kersti Alm, and Head of Communication, Lisa Bodily, have recently contributed to the June 2023 issue of the German BIOSpektrum journal. Their application article sheds light on how HoloMonitor’s technology is applied for non-invasive live cell analysis.
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Notice that Interim Report 4 2022/23 will be published on June 26, 2023
PHI changes the date for publication of Interim Report 4 2022/23 to June 26, 2023.
The PHI Story
Get to know PHI! PHI provides innovative tools that let you continuously image and monitor your cells directly in your incubator.
PHI’s new HoloMonitor M4FL premiers at major scientific conferences
PHI introduces the HoloMonitor M4FL system to the global scientific community at two major scientific conferences this June.
PHI AB’s warrant exercise registered with the Swedish Companies Registration Office
PHI today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office.